The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...